INTENSIVE CHEMOTHERAPY VS IMMUNE STIMULATING THERAPY OF HIV-INFECTED PATIENTS (PTS) WITH KAPOSI'S SARCOMA (KS) (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


INTENSIVE CHEMOTHERAPY VS IMMUNE STIMULATING THERAPY OF HIV-INFECTED PATIENTS (PTS) WITH KAPOSI'S SARCOMA (KS) (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A10 1992. Unique Identifier : AIDSLINE ICDB/92680741
Rosenthal CJ; Papandreou C; Nandivada N; SUNY-Health Science Center at Brooklyn, Brooklyn, NY

Abstract: Twenty-nine previously untreated HIV-seropositive men with histologically diagnosed extensive KS were sequentially entered between January 1985 and July 1991 in one of these two regimens: (A) Vinblastine 4 mg/m2 iv bolus q 3 wk + INF (Intron A; Schering) 10 x 10(6) U/m2 tiw for at least 6 mo (Vb INF); (B) cyclophosphamide 350 mg/m2 iv day (d) 1; Oncovin 1 mg/d iv continuous infusion (IVCI) d 1,2; prednisone 40 mg/m2 po qd d 1-5; bleomycin 5 U/m2/d IVCI d 1-5; Matulane 100 mg/m2 po qd d 1-5 (COPBM) q 4 wk for a total of 4 cycles followed by INF 10 x 10(6) U/m2 tiw for 6 mo. All pts received other supportive treatment. There were 14 homosexuals, 11 IVDA and 4 homosexual IVDA. Their median age was 32. Seven pts had PCP prior to their entry in this study. Pretreatment staging revealed visceral involvement in 8 pts. Data are presented in a table. A significantly (p less than 0.01) higher percentage of pts achieved PR in group B but the overall survival was the same. All 4 pts who progressed in regimen A when crossed over to regimen B reached MR (mean duration of 22 +/- 4 wk). Pretreatment CD4-positive lymphocyte counts and NK activity improved in all responders (in group B only after induction treatment was completed). Toxicity included moderate granulocytopenia and thrombocytopenia and flulike syndrome due to INF leading to a 15% dropout. We conclude that Vb INF regimen, while less effective than COPBM in inducing PR, led to equally effective control of advanced KS. When disease progressed, COPBM was still able to induce temporary PR or MR.
Keywords: Adult Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycin/ADMINISTRATION & DOSAGE Comparative Study Cyclophosphamide/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Homosexuality Human HIV Infections/*COMPLICATIONS Immunotherapy Interferon Alfa, Recombinant/*THERAPEUTIC USE Male Prednisone/ADMINISTRATION & DOSAGE Procarbazine/ADMINISTRATION & DOSAGE Sarcoma, Kaposi's/DRUG THERAPY/*ETIOLOGY/*THERAPY Vinblastine/*THERAPEUTIC USE Vincristine/ADMINISTRATION & DOSAGE CLINICAL TRIAL ABSTRACT

KWDadultantineoplasticagents,combined/KWDtherapeuticusebleomycin/administration&dosagecomparativestudycyclophosphamide/administration&dosagedoxorubicin/administration&dosagehomosexualityhumanhivinfections/KWDcomplicationsimmunotherapyinterferonalfa,recombinant/KWDtherapeuticusemaleprednisone/administration&dosageprocarbazine/administration&dosagesarcoma,kaposi's/drugtherapy/KWDetiology/KWDtherapyvinblastine/KWDtherapeuticusevincristine/administration&dosageclinicaltrialabstract
921130
M92B0899

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .